CRISPR Screens Identify the ATPase VCP as a Druggable Therapeutic Vulnerability in Cholangiocarcinoma

Cholangiocarcinoma (CCA) remains a lethal malignancy with limited therapeutic options. Through genome-wide CRISPR-Cas9 screening, we identified the ATPase valosin-containing protein (VCP) as a critical dependency in CCA. Compound screens revealed that the VCP inhibitor CB-5339 potently suppresses CCA proliferation in a panel of patient derived organoids by inducing cellular senescence. It is known that senescent cells persist and this can contribute to therapy resistance. To address this, we combined CB-5339 with senolytic agents (ABT-263 and conatumumab), which selectively eliminate senescent CCA cells, achieving enhanced tumor suppression in vitro and in vivo. Clinical analysis showed that VCP overexpression in CCA patients correlates with poor prognosis. Our study unveils a “one-two punch” strategy, targeting VCP-mediated senescence followed by senolytic clearance, offering a promising therapeutic approach for CCA. HuCCT1 and RBE cells were seeded in 6-well plates at 60–70% confluency and treated with 2 μM CB-5339 (MedChemExpress, HY-128724) for 7 days.